Marketresearchnews

Monday 6 January 2020

Intraductal Papilloma Market to Observe Strong Development by 2019

An intraductal papilloma is a benign, or noncancerous, breast tumour that forms in a milk duct and is made of gland and fibrous tissue as well as blood vessels. These generally appear as lumps after breast examination and may cause nipple discharge or bleeding. Intraductal papilloma most commonly occur in women between ages 35 and 55. Central/solitary papillomas are generally benign while multiple papillomas, have been associated with a slightly higher risk of breast cancer.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4450

The market for global intraductal papilloma is constrained by the lack of awareness, high cost of surgery, complications of the surgery, lack of focus on women health in the developing and poorer regions of the world etc. Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to minimal invasive surgeries procedures such as needle aspiration biopsy surgeries etc.

The symptoms of intraductal papilloma are breast enlargement, inversion of the nipple, thickening or swelling of part of the breast, changes to the breast or nipple skin area, such as dimpling, redness, scaling, peeling etc. Multiple papillomas consist of about 10 % of all intraductal papillomas. Intraductal papilloma comprise approximately 10% of all benign breast tumour types and are benign lesions with an incidence of approximately 2-3% in humans. Risk factors such as obesity, alcohol consumption, postmenopausal hormone therapy, having the first child after the age of 35, or never having a child, medications containing estrogen and progesterone such as birth control pills, menstrual cycle abnormalities, physical inactivity, not breastfeeding the child etc. increase the chances of intraductal papillomas.

The global intraductal papilloma market is expected to reach USD 8.4 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.

Segments:

The global intraductal papilloma market has been segmented on the basis of type, diagnosis, treatment, and end user.

Based on type, the market has been segmented as central/solitary papillomas, peripheral/multiple papillomas and others.

Based on diagnosis, the market has been segmented as examination, ultrasonography, biopsy, mammogram/galactography, ductograms, Computerized Tomography (CT) and others.

Based on surgery, the market has been segmented as microdochectomy, total duct excision, drugs and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Regional Analysis

The Americas account for a significant market share owing to extensive volume of surgeries performed and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drive the intraductal papilloma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US spends high on its healthcare, which accounts for 16% of GDP, further cruising the market for intraductal papilloma treatment.

Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.

Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.

Key Players in the Global Intraductal papilloma Market

Some of key players profiled in the report are Allergen plc, Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals Inc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/sample_request/4450

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Global Healthcare Revenue Cycle Management Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2027

Market Scenario

The report covers the latest trends impacting the market to provide the most accurate forecasts and predictions. By correlating the historical data with upcoming market dynamics, our analysts can make highly astute projections. MRFR’s report includes a thorough analysis of the global healthcare revenue cycle management market segmented according to type, application, end-user, and region. Growth opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/878

The global healthcare revenue cycle management market is touted to exhibit a healthy 12.2% CAGR during the assessment period (2017-2027), as per a new market report by Market Research Future (MRFR).

The rising costs of surgeries and overall healthcare has induced the need for hospitals to lean towards technology to reduce the burden. Healthcare revenue cycle management (RCM) is a system in the healthcare cycle which relies on electronic health records (EHRs) and automation to expedite outpatient billing and reduce wait times. The growing numbers of hospitals and clinics, rising adoption rate of RCM software, recovery audits, and preference for integrated healthcare systems are factors expected to drive market demand during the forecast period.

Segmentation:

Based on the product type, the market can be segmented into advanced integrated software and standalone software. The advanced integrated software accrues almost 81.4% of the total revenue generated in the market and is blessed with the fastest CAGR of 12.3% during the forecast period.

Component-based segmentation of the market includes software and services. The software segment is gaining precedence considerably in the global market owing to its applicational ease, and it commanded the largest market share in 2016.

Deployment-wise segmentation comprises on-premise and on-cloud/web-based. On-cloud section is gaining much traction. However, on-premise application held the largest share of the market in 2016 as many still find complete cloud solution a bit difficult to operate.

Based on end-users, the market can be segmented into hospitals and ambulatory services. Hospitals hold the major share, and many rely heavily on its assistance in cases of emergency.

Regional Analysis:

The geographical analysis of the market covers namely the Americas, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA).

The Americas take the onus of generating the maximum revenue as the region has this tendency to rely heavily on advanced technology. Advanced infrastructure accommodates such a wide-spread implementation of RCM software which benefits all. In addition, the market is profiting much from several major players presence in the segment, along with a scheduled substantial healthcare expenditure every year.

Europe is holding the second position, and it can be attributed to increasing government support in research and development. Other features such as well-developed healthcare infrastructure and considerable healthcare funding are quite similar in their impact to that of the Americas.

The APAC is all set to register the fastest growth. Emerging economies of the region are changing the healthcare sector remarkable, and many of them are evolving as a medical tourism hub which as a consequence, is assertively impacting the global RCM market. However, the MEA is still lagging much behind as the region has quite a few poor and slow developing countries.

Browse Complete 122 Pages Premium Research Report Enabled with 129 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/healthcare-revenue-cycle-management-market-878

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Bioinformatics Market Dynamics, Forecast, Analysis and Supply Demand 2019

Market scenario:

The Global Bioinformatics Market is expected to exhibit a CAGR of 19.8% over the forecast period from 2016 to 2022, according to a new research report from Market Research Future (MRFR). The global bioinformatics market is mainly driven by the growing demand in developing countries in enhancing their healthcare sector and making advanced healthcare modalities available to patients.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2265

The growing demand for electronic healthcare data storage is likely to be a major driver for the global bioinformatics market. The reliance on manual and paper-based documentation of healthcare procedures has resulted in unmanageable volumes of healthcare information, which can make it difficult to locate individual patients and their medical history. Electronic healthcare records, which are but the first step of the bioinformatics market, have already become widely popular in developed countries due to the benefits they present in terms of consistent data storage over the long term and ease in acquiring specific details at any given time. The growing demand for e-prescriptions and online pharmacies is likely to further the cause of the bioinformatics market over the forecast period, as strong bioinformatics networks are needed to operate and manage e-prescriptions and the related documentation.

The growing demand for strong data storage facilities in medical research is also likely to be a major driver for the global bioinformatics market. Bioinformatics plays a key role in genetic studies, in which it helps track details regarding multiple genes and their multifarious associations with the indicators being studied in the respective trial. The growing dependence on genetic studies in cancer research is likely to be a major driver for the global bioinformatics market over the forecast period, as cancer research has received strong government backing across the world. Other medical research applications are also likely to make use of bioinformatics systems on a large scale in the coming years, leading to steady growth of the global bioinformatics market over the forecast period.

Study Objectives of Bioinformatics Market:

To provide detail analysis of the market structure along with forecast for the next 7 years about various segments and sub-segments of the global bioinformatics market.
To provide insights about factors affecting the market growth.
To analyze the market based on price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and future growth prospective.
To provide country level analysis of the market for segments by drug application, by technology, by sector and services and its sub-segments.
To provide overview about key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape of the market.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Bioinformatics market.

Intended Audience

Bioinformatics service providers
Bioinformatics manufacturers
Research and development (R&D) companies
Government research laboratories
Government and independent regulatory authorities

Segmentation:

The global bioinformatics market is segmented on the basis of application, service, sector, and region in the MRFR report in order to provide a comprehensive coverage of all important factors related to the market’s growth prospects over the forecast period.

The bioinformatics market has been segmented on the basis of application into genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences, and others. Increasing interest in genetic studies is likely to be a major driver for the global bioinformatics market over the forecast period.

On the basis of services and technology, the global bioinformatics market is segmented into data warehousing, sequence analysis, sequence manipulation, and others.

Key Players for Bioinformatics Market:

Agilent Technologies,
Illumina, Inc.,
QIAGEN N. V, and Thermo Fisher Scientific Inc.,
Dassault Systèmes,
QIAGEN and others.

Regional Analysis:

The global bioinformatics market is segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The global bioinformatics market is dominated by the Americas and Europe in terms of region due to the presence of strong telecommunications infrastructure in these regions to support advanced bioinformatics processes. The presence of a strong wireless internet and other telecommunication features is crucial for a bioinformatics system to function productively. This has actually been one of the key factors that has held back the bioinformatics market in underdeveloped regions.

In April 2019, researchers from UCLA announced a plan to develop a system that would allow scientists in developing countries to use cloud computing and big data analytics to accelerate the development of the bioinformatics field in their own countries. Efforts such as these are the result of the growing awareness of the disparity in terms of telecommunications infrastructure between developed and developing countries.

Asia Pacific is likely to exhibit the fastest growth over the forecast period due to the increasing efforts from governments in the region to incorporate powerful bioinformatics programs into the day-to-day functioning of their country’s healthcare sector.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bioinformatics-market-2265

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Regenerative Medicine Market Dynamics, Forecast, Analysis and Supply Demand 2019

Market Scenario:

The Global Regenerative Medicine Market is growing steadily. Factors that influence the regenerative medicine market are increasing advancement in healthcare technology, increasing advance technology in regenerative medicine market, increasing prevalence of chronic diseases, increasing growth in stem cell technology and others. Globally the market for regenerative medicine is expected to grow at the rate of about 25.4% from 2016 to 2022.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2220

Investments are likely to flow towards the regenerative medicine market over the next couple of years. In addition, the support extended by the government for drug development is poised to revolutionize the future trajectory of the global market. It is also likely to benefit from technological advancements in the market.

Stem cell technology is gaining traction in the healthcare sector. Its accelerated adoption in the field of medical science is also anticipated to have a favorable impact on the expansion of the regenerative medicine market. The players of the market are forecasted to capitalize on the gap prevailing between the demand and supply for organs. However, factors such as stringent regulations, and the high cost of the treatment are expected to check the proliferation of the regenerative medicine market through the projection period.

Market Segmentation:

on the basis of material, the regenerative medicine market has been segmented into synthetic materials, genetically engineered materials, pharmaceuticals, biologically derived materials, and others.

On the basis of therapy, the global regenerative medicine market has been segmented into stem cell biology, cellular therapy, tissue engineering, and others.

On the basis of application, the regenerative medicine market has been segmented into cord blood, oncology, urology, orthopedics, neurology, dermatology, cardiovascular, orthopedic and others.

Competitive Dashboard:

Some of the key players profiled in the report are Cook Biotech, Organogenesis, Stryker and RTI surgical, Baxter International, Inc., Osiris Therapeutics, CryoLife, Sanofi, LifeSciences, Advanced Cell Technology, BioMimetic Therapeutics, LifeCell Kinetic Concepts, StemCellsInc, and Medtronic.

Regional Analysis:

The global regenerative medicine market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is currently holding the largest share of the market, accounting for 44% share. It is expected to grow significantly at a CAGR of 22.3% during the forecast period. The factors such as developments in healthcare technology, presence of advanced healthcare infrastructure, increasing burden of chronic diseases, etc.

Europe has gained control over the second-largest share of the market. It is expected to strike a high CAGR of 22.5% over the assessment period. The availability of funds coupled with the government’s support is likely to accelerate research & development activities. This, in turn, is prognosticated to boost the growth trajectory of the regional regenerative medicine market in the upcoming years.

Asia Pacific is a highly lucrative market and is expected to remain so across the review period. The rapid developments in the healthcare sector and growing patient pool are anticipated to drive the expansion of the regenerative medicine market in the region. It is estimated to mark a relatively higher CAGR and emerge as the fastest growing regional market in the foreseeable future.

Industry News:

In November 2018, 3D.FAB, a French additive manufacturing platform, has announced that it is working on the development of a “living bandage” using direct additive manufacturing and 3D bioprinting for treating damaged tissues.

In December 2018, Food and Drug Administration has sent Genetech, a CA-based biotechnology subsidiary of Roche, and other firms and providers offering stem cell treatments warning letters to notify about agency's regenerative medicine policy framework.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Friday 3 January 2020

Latest Study Offers Detailed Insights on Nasal Drug Delivery Market 2019

Market Scenario

The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.

Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2696

Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists.

However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.

Segmentation

The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.

Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.

Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.

Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.

Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.

Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.

The global market, by end user, has been divided into home care settings and hospitals & clinics.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region.

Key Players

GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.

Regional Market Summary

Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.

Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.

Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.

Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.

Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.

The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.

Browse Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Thursday 2 January 2020

Precision Medicine Market in depth study and analysis published, 2019

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.

The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2025. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2025.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/925

Precision medicine evolved from the concept that same medicine cannot function equally for two different individuals with the same disease as they have different gene structure. At the same time, medication depends on how well patients can respond to its dosage. Hence, the need for precision medicine. Market Research Future (MRFR), in their report, has included various drivers and segments that can produce a reliable prediction for the future market. Prevalent diseases such as cancer, diabetes, and others are boosting the precision medicine market as treatment of such diseases gets a better result with personalized medicine structure. Furthermore, its impact can significantly lower the cost of treatment.

However, a personal data breach can be seen as a major precision medicine market growth prohibition. The diagnostic cost can incur a high cost, stringent government policies, the risk with hardware and software failure, and lack of medical framework can hold back the market during the forecast period.

Key Players for Global Precision Medicine Market:

Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine

Key Findings:

The global precision medicine market is expected to reach USD 88.64 billion by 2025.
By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2025.
By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2025.

Segmentation

The global precision medicine market has been segmented into ecosystem players, sub-markets, and therapeutics.

Based on ecosystem players, the global market has been segmented into pharmaceuticals and biotechnology companies, diagnostic companies, healthcare IT specialists/big data companies, and clinical laboratories. The diagnostic tool companies segment accounted for a market value of USD 16.27 million in 2017.

Based on sub-markets, the global market has been segmented into companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics (PGX), molecular diagnostics, and others.

Based on therapeutics, the global market has been segmented cancer/oncology, cardiovascular disease (CVD), central nervous system, infectious diseases, and others.

Regional Analysis

Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Plasma Fractionation Market Trends and Drivers Analysis 2019 To 2023

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.

In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7397

Global Plasma Fractionation Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.

Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.

However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.

Segmentation

The global plasma fractionation market is segmented based on product, application, end user, and region.

The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.

Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.

Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.

On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com